Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Business IPO

Symbiotec Pharmalab IPO oversubscribed 71 times

Analysis based on 21 articles · First reported Aug 19, 2026 · Last updated Aug 27, 2026

Sentiment
60
Attention
4
Articles
21
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The IPO's strong subscription indicates robust investor appetite for pharmaceutical and biotechnology companies in India, potentially boosting sentiment for the sector. The listing is expected to generate significant returns for investors, given the grey market premium of Rs 345, and may attract further capital to the API manufacturing segment.

Pharmaceuticals Biotechnology

Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, launched its initial public offering (IPO) on August 24, 2026, with a price band of Rs 938-988 per share. The issue, which closed on August 27, 2026, comprised a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore by selling shareholders Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund III. The IPO was subscribed 71.26 times, driven by strong demand from non-institutional investors (12.18x) and retail investors. The company raised Rs 526.19 crore from anchor investors ahead of the issue. Proceeds from the fresh issue will be used for debt repayment and general corporate purposes. The company is a global leader in corticosteroid and steroidal-hormone APIs, with a backward-integrated manufacturing model. The shares are expected to list on the BSE and NSE on September 1, 2026.

100 Symbiotec Pharmalab launched IPO
90 Symbiotec Pharmalab received IPO bids
80 Symbiotec Pharmalab raised anchor funds
70 Satwani Holdings LLP offered shares
70 Rosewood Investments offered shares for sale
60 Symbiotec Pharmalab planned listing
50 Symbiotec Pharmalab planned debt repayment
30 JM Financial acted as lead manager Symbiotec Pharmalab
priv
The company is the issuer of the IPO, raising Rs 1,757 crore. The oversubscription reflects strong market confidence in its business model and growth prospects, likely leading to a successful listing and enhanced capital for expansion.
Importance 100.0 Sentiment 80.0
priv
As a promoter and selling shareholder, Satwani Holdings LLP is offloading shares in the OFS, realizing gains from the IPO. The strong demand benefits its exit valuation.
Importance 70.0 Sentiment 60.0
priv
As an investor selling shareholder, Rosewood Investments is selling its stake in the OFS, benefiting from the high valuation and strong subscription.
Importance 60.0 Sentiment 60.0
priv
As an investor selling shareholder, India Business Excellence Fund III is selling its stake in the OFS, capitalizing on the favorable market conditions.
Importance 60.0 Sentiment 60.0
stock
As a book-running lead manager, JM Financial earns fees and enhances its reputation in the IPO market.
Importance 50.0 Sentiment 45.0
priv
As a book-running lead manager, JM Financial earns fees and enhances its reputation by managing a highly successful IPO.
Importance 50.0 Sentiment 60.0
priv
As a book-running lead manager, Avendus Capital earns fees and enhances its reputation by managing a highly successful IPO.
Importance 50.0 Sentiment 60.0
priv
As a book-running lead manager, Motilal Oswal Investment Advisors earns fees and enhances its reputation by managing a highly successful IPO.
Importance 50.0 Sentiment 60.0
stock
As a book-running lead manager through its Indian subsidiary, Nomura Holdings earns fees and enhances its reputation by managing a highly successful IPO.
Importance 50.0 Sentiment 60.0
subs
State Bank of India — SBI Securities assigned a 'Subscribe' recommendation, influencing investor decisions and potentially boosting subscription.
Importance 40.0 Sentiment 45.0
per
As a promoter, Anil Satwani's stake will be diluted post-IPO, but the successful offering enhances the company's financial standing and his wealth.
Importance 40.0 Sentiment 60.0
per
As a promoter, Kashish Satwani's stake will be diluted post-IPO, but the successful offering enhances the company's financial standing and his wealth.
Importance 40.0 Sentiment 60.0
per
As a promoter, Sushil Sarwan's stake will be diluted post-IPO, but the successful offering enhances the company's financial standing and his wealth.
Importance 40.0 Sentiment 60.0
cnt
The IPO is part of India's vibrant capital markets, reflecting the country's growing pharmaceutical sector and investor confidence in domestic companies.
Importance 30.0 Sentiment 50.0
exch
The BSE will host the listing of Symbiotec Pharmalab shares, adding to its trading volumes and reinforcing its position as a primary listing venue.
Importance 30.0 Sentiment 50.0
+ 8 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.